Loading...

Home
Stock
MRSN

MRSN News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

MRSN News

Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook

Feb 24 2026Yahoo Finance

Day One Acquires Mersana for $25 per Share, Expanding Oncology Pipeline

Jan 06 2026Globenewswire

Halper Sadeh Investigates Udemy and Others for Potential Violations

Dec 24 2025PRnewswire

Alexander & Baldwin Acquired for $21.20 per Share, Valuing Deal at $2.3 Billion

Dec 23 2025Globenewswire

Halper Sadeh Investigates Mersana's Sale to Day One for Shareholder Rights Violations

Dec 17 2025PRnewswire

Mersana's $285M Deal with Day One Under Investigation for Fiduciary Breaches

Dec 16 2025PRnewswire

Halper Sadeh Investigates First Foundation's Merger with FirstSun Capital

Dec 14 2025Globenewswire

Mersana Therapeutics to be Sold to Day One Biopharmaceuticals for Up to $55.25 per Share

Dec 12 2025PRnewswire

MRSN Events

Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics

Day One Biopharmaceuticals announced the close of its acquisition of Mersana Therapeutics, following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.

Mersana Therapeutics Announces Q3 Earnings Per Share of ($1.51), Below Consensus Estimate of 89 Cents

Reports Q3 revenue $11M, consensus $15.5M. Cash and cash equivalents as of September 30, 2025 were $56.4 million. The company continues to expect that its capital resources will be sufficient to support its current operating plan commitments into mid-2026

MRSN Monitor News

No data

No data

MRSN Earnings Analysis

No Data

No Data

People Also Watch